Back to News
Market Impact: 0.25
Raymond James Initiates Coverage of Seaport Therapeutics at Strong Buy
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Raymond James initiated coverage of Seaport Therapeutics (NASDAQGS: SPTX) on September 25, 2026, with a Strong Buy recommendation. The positive analyst action follows other recent updates to the company’s outlook, including coverage activity from HC Wainwright & Co. on September 10.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
RJF0.10
SPTX0.72
More News
- Supply glut, lab-grown alternatives: What's behind the fall of diamond prices to record lows
- Trump’s new Medicaid rules will kick in, and GOP states are tougher. Someone may be too frail to work but can’t afford to see a doctor to prove it
- Insurers claim AI is already increasing healthcare costs
- Hershey Trust Co. sells $5.05 million in Hershey Co. stock
- ‘Godfather of AI’ explains how humanity could end: Even without a bad actor, AI ‘may derive subgoals that cause it to want to get rid of people’
- White House moves to block $810 million in funding through pocket rescission
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis